{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:38:57Z","timestamp":1793093937932,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ogla.2025.02.004","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:59:52Z","timestamp":1741031992000},"page":"384-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1016","volume":"8","author":[{"given":"David L.","family":"Wirta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif M.","family":"El-Harazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Tepedino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bacharach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2025.02.004_bib1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","article-title":"Glaucoma","volume":"377","author":"Quigley","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ogla.2025.02.004_bib2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ogla.2025.02.004_bib3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/OPTH.S340386","article-title":"Efficacy and patient tolerability of omidenepag isopropyl in the treatment of glaucoma and ocular hypertension","volume":"16","author":"Matsuo","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2147\/OPTH.S63760","article-title":"Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs","volume":"8","author":"Schmier","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1089\/jop.2021.0077","article-title":"Phase 2b, randomized, 3-month, dose-finding study of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: the ANGEL study","volume":"38","author":"Wirta","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ogla.2025.02.004_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10384-021-00844-6","article-title":"Prostanoid receptor agonists for glaucoma treatment","volume":"65","author":"Aihara","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib7","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/OPTH.S44708","article-title":"Managing adverse effects of glaucoma medications","volume":"8","author":"Inoue","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib8","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bjophthalmol-2016-309023","article-title":"Ocular hypotensive effect of the novel EP3\/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study","volume":"101","author":"Miller Ellis","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archopht.1996.01100140137004","article-title":"A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study","volume":"114","author":"Mishima","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0161-6420(96)30749-5","article-title":"Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2025.02.004_bib12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bjo.85.8.983","article-title":"Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension","volume":"85","author":"Zhang","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2024.02.010","article-title":"Omidenepag isopropyl versus timolol in patients with glaucoma or ocular hypertension: two randomized phase 3 trials (SPECTRUM 4 and 3)","volume":"263","author":"Bacharach","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib14","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1167\/iovs.14-16181","article-title":"IOP-lowering effect of ONO-9054, A novel dual agonist of prostanoid EP3 and FP receptors, in Monkeys","volume":"56","author":"Yamane","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2025.02.004_bib15","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1167\/iovs.15-18166","article-title":"A novel dual agonist of EP3 and FP receptors for OAG and OHT: safety, pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy volunteers","volume":"56","author":"Suto","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2025.02.004_bib16","first-page":"1","article-title":"European glaucoma society terminology and guidelines for glaucoma, 5th Edition","volume":"105","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2025.02.004_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/bjo.2007.135111","article-title":"Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials","volume":"93","author":"Honrubia","year":"2009","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419625000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419625000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:31:33Z","timestamp":1777696293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419625000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2589419625000328"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2025.02.004","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2025.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00c2\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}